The Retinoblastoma Susceptibility Gene RB-1 in Multiple Myeloma

Bibliography

• Lokhorst H. M., Boom S. E., Bast B. J.E.G., Peters P. J., Tedder T. F., Gerdes J., Petersen E., Ballieux R. Novel type of proliferating lymphoplasmocytoid cell with a characteristic spotted immunofluorescence pattern. J. Clin. Invest 1987; 79: 1401–1411
   PubMed Web of Science ®Google Scholar
• Greipp P. R., Katzmann J. A., O'Fallon W. M., Kyle R. A. Value of β2 microglobulin and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1982; 72: 219–223
   Google Scholar
• Greipp P. R., Witzig T. E., Gonchoroff N. J., Habermann T. M., Katzmann J. A., Kyle R. A. Immunofluorescence labeling indices in myeloma and related monoclonal gammapathies. MAVO Clin. Proc. 1987; 62: 969–977
   PubMed Web of Science ®Google Scholar
• Takahashi T., Lim B., Jamal N., Tritchler D., Lockwood G., McKinney S., Bergsagel D. E., Messner H. A. Colony growth and self renewal of plasma cell precursors in multiple myeloma. J. Clin. Oncol. 1985; 3: 1613–1623
   PubMed Web of Science ®Google Scholar
• Bakkus M. H. C., Heirman C., Van Riet I., Van Camp B., Thielemans K. Evidence that multiple myeloma Ig heavy chain VDJ genes contain somatic mutations but show no intraclonal variation. Blood 1992; 80: 2326–2335
   PubMed Web of Science ®Google Scholar
• Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. H., Kuramoto A., Kishimoto T. Autocrine generation and essential requirement of BSF‐2/IL‐6 for human multiple myeloma. Nature 1988; 332: 83–85
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma‐cell growth and differentiation by interleukin‐6. Blood 1989; 73: 517–526
   PubMed Web of Science ®Google Scholar
• Bataille R., Barlogie B., Lu Z. Y., Rossi J. F., Lavabre‐Bertrand T., Beck T., Wijdenes J., Brochier J., Klein B. Biologic effects of anti‐interleukin‐6 murine monoclonal antibody in advanced multiple myeloma. Blood 1995; 86: 685–691
   PubMed Web of Science ®Google Scholar
• Carter A., Merchau S., Silvian‐Draxler I., Tatarsky I. The role of interleukin‐1 and tumor necrosis factor‐α in human multiple myeloma. Br. J. Haematol. 1990; 74: 424–431
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Gu Z. J., Lu Z. Y., Yazukawa K., Yancopoulos G. D., Turner K., Shoyab M., Taga T., Kishimoto T., Bataille R., Klein B. Ciliary neurotropic factor, interleukin II. leukemia inhibitory factor. and oncostatin M are growth factors for human myeloma cell lines using the interleukin 6 signal transducer gp 130. J. Exp. Med. 1994; 179: 1337–1342
   PubMed Web of Science ®Google Scholar
• Nishimoto N., Ogata A., Shima Y., Tani Y., Ogawa H., Nakagawa M., Sugiyama H., Yoshizaki K., Kishimoto T. Oncostatin M. leukemia inhibitory factor, and inter‐leukin‐6 induce the proliferation of human plasmocytoma cells via the common signal transducer. gp 130. J. Exp. Med. 1994; 179: 1343–1349
   PubMed Web of Science ®Google Scholar
• Juge‐Morineau N., Francois S., Puthier D., Godard A., Bataille R., Amiot M. The gp 130 family cytokines IL‐6, LIF and OSM but not IL‐11 can reverse the anti‐proliferative effect of dexamethasone on human myeloma cells. Br. J. Haematol. 1995; 90: 707–710
   PubMed Web of Science ®Google Scholar
• Klein B., Zhang X. G., Lu Z. Y., Bataille R. Interleukin‐6 in human multiple myeloma. Blood 1995; 85: 863–872
   PubMed Web of Science ®Google Scholar
• Lu Z. Y., Zhang X. G., Rodriguez C., Wijdenes J., Gu Z. J., Morel‐Foumier B., Harousseau J. L., Bataille R., Rossi J. F., Klein B. Interleukin‐10 is a proliferation factor but not a differentiation factor for human myeloma cells. Blood 1995; 85: 2521–2527
   PubMed Web of Science ®Google Scholar
• Lay J. L., Zandeckj M., Mary J. Y., Bemardi F., Izydorczyk V., Flactif M., Morel P., Jouet J. P., Bauters F., Facon T. Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis. Blood 1995; 85: 2490–2497
   PubMed Web of Science ®Google Scholar
• Selvanayagam P., Blick M., Narni F., Van Tuinen P., Ledbetter D. M., Alexanian R., Saundera G. F., Barlogie B. Alteration and abnormal expression of the c‐myc oncogene in human multiple myeloma. Blood 1988; 71: 30–35
   PubMed Web of Science ®Google Scholar
• Greil R., Fasching B., Loidl P., Huber H. Expression of the c‐myc protooncogene in multiple myeloma and chronic lymphocytic leukemia: an in situ analysis. Blood 1991; 78: 180–191
   PubMed Web of Science ®Google Scholar
• Pettersson M., Jernberg‐Wiklund H., Larsson L. G., Sundström C., Givol I., Tujimoto Y., Nilsson K. Expression of the bcl‐2 gene in human multiple myeloma cell lines and normal plasma cells. Blood 1992; 79: 495–502
   PubMed Web of Science ®Google Scholar
• Neri A., Murphy J. P., Cro L., Ferrero D., Tarella C., Baldini L., Dalla‐Favera R. Ras oncogene mutation in multiple myeloma. J. Exp. Med. 1989; 170: 1715–1725
   PubMed Web of Science ®Google Scholar
• Corradini P., Ladetto M., Voena C., Palumbo A., Inghirami G., Knowles D. M., Boccadoro M., Pileri A. Mutational activation of N‐ and K‐ras oncogenes in plasma cell dyscrasia. Blood 1993; 81: 2708–2713
   PubMed Web of Science ®Google Scholar
• Mazars G. R., Portier M., Zhang X. G., Jourdan M., Bataille R., Theillet C., Klein B. Mutations of the p53 gene in human myeloma cell lines. Oncogene 1992; 7: 1015–1018
   PubMed Web of Science ®Google Scholar
• Preudhomme C., Facon T., Zandecki M., Vanrumbeke M., Laï J. L., Nataf E., Loucheux‐Lefebvre M. H., Kerckaert J. P., Fenaux P. Rare occurrence of P53 gene mutations in multiple myeloma. Br. J. Haematol. 1992; 81: 440–443
   PubMed Web of Science ®Google Scholar
• Neri A., Baldini L., Trecca D., Cro L., Polli E., Maiolo A. T. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128–135
   PubMed Web of Science ®Google Scholar
• Santhanam U., Ray A., Sehgal P. B. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. 1991; 88: 7605–7609
   PubMed Web of Science ®Google Scholar
• Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Seminars in Hematology 1995; 32: 4–19
   PubMed Web of Science ®Google Scholar
• Fiedler W., Weh H. J., Hossfeld D. K. Comparison of chromosome analysis and BCL1 rearrangement in a series of patients with multiple myeloma. Br. J. Haematol. 1992; 81: 58–61
   PubMed Web of Science ®Google Scholar
• Akiyama N., Tsuruta H., Sasaki H., Sakamoto H., Hamaguchi M., Ohmura Y., Seto M., Ueda R., Hirai H., Yazaki Y., Sugimura T., Terada M. Messenger RNA levels of five genes located at chromosome l lq13 in B‐cell tumors with chromosome translocation t(11;14)(q13;q32). Cancer Res. 1994; 54: 377–379
   PubMed Web of Science ®Google Scholar
• Palumbo A. P., Boccadoro M., Battaglio S., Corradini P., Tsichlis P. N., Huebner K., Pileri A., Croce C. M. Human homologue of moloney leukemia virus integration‐4 locus (MLVI‐4), located 20 kilobases 3′ of the c‐myc gene, is rearranged in multiple myeloma. Cancer Res. 1990; 50: 6478–6482
   PubMed Web of Science ®Google Scholar
• Hamel P. A., Gallie B. L., Phillips R. A. The retinoblastoma protein and cell cycle regulation. Trends in Genetics 1992; 8: 180–185
   PubMed Web of Science ®Google Scholar
• Huang H. J. S., Yee J. K., Shew J. Y., Chen P. L., Bookstein R., Friedmann T., Lee E. Y.H.P., Lee W. H. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 1988; 242: 1563–1566
   PubMed Web of Science ®Google Scholar
• Lee W. H., Bookstein R., Hong F., Young L. J., Shew J. Y., Lee E. Y.H. P. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 1987; 235: 1394–1399
   PubMed Web of Science ®Google Scholar
• Fung Y. K. T., Murphree A. L., T'Ang A., Qian J., Hinrichs S. H., Benedict W. F. Structural evidence for the authenticity of the human retinoblastoma gene. Science 1987; 236: 1657–1661
   PubMed Web of Science ®Google Scholar
• Grand R. J. A., Byrd P. J., Grabham P. W., Gregory C. D., Huen D. S., Merrick R. M., Young L. S., Gallimore P. H. The expression of the retinoblastoma gene product Rb1 in primary and adenovirus‐transformed human cells. Oncogene 1989; 4: 1291–1298
   PubMed Web of Science ®Google Scholar
• Lee W. H., Shew J. Y., Hong F. D., Sery T. W., Donoso L. A., Young L. J., Bookstein R., Lee E. Y. H. P. The retinoblastoma susceptibility gene encodes a nuclear phospho‐protein associated with DNA binding activity. Nature 1987; 329: 642–645
   PubMed Web of Science ®Google Scholar
• Mihara K., Cao X. R., Yen A., Chandler S., Driscoll B., Murphree A. L., T'Ang A., Fung Y. K. T. Cell cycle‐dependent regulation of phosphorylation of the human retinoblastoma gene product. Science 1989; 246: 1300–1303
   PubMed Web of Science ®Google Scholar
• Chen P. L., Scully P., Shew J. Y., Wang J. Y. J., Lee W. H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell 1989; 58: 1193–1198
   PubMed Web of Science ®Google Scholar
• Furukawa Y., DeCaprio J. A., Freedman A., Kanakura Y., Nakamura M., Ernst T. J., Livingston D. M., Griffin J. D. Expression and state of phosphorylation of the retinoblastoma susceptibility gene product in cycling and non‐cycling human hematopoietic cells. Proc. Natl. Acad. Sci. 1990; 87: 2770–2774
   PubMed Web of Science ®Google Scholar
• Hatzfeld J., Li M. L., Brown E. L., Sookdeo H., Lesveque J. P., O'Toole T., Gurney C., Clark S. C., Hatzfeld A. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor PI or Rb oligonucleotides. J. Exp. Med. 1991; 174: 925–929
   PubMed Web of Science ®Google Scholar
• Kumar R., Atlas I. Interferon a induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc. Natl. Acad. Sci. 1992; 89: 6599–6603
   PubMed Web of Science ®Google Scholar
• Resnitzky D., Tiefenbrun N., Berissi H., Kimchi A. Interferons and interleukin 6 suppress phosphorylation of the retinoblastoma protein in growth‐sensitive hematopoietic cells. Proc. Natl. Acad. Sci. 1992; 89: 402–406
   PubMed Web of Science ®Google Scholar
• DeCaprio J. A., Ludlow J. W., Figge J., Shew J. Y., Huang C. M., Lee W. H., Marsilio E., Paucha E., Livingston D. M. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988; 54: 275–283
   PubMed Web of Science ®Google Scholar
• Dyson N., Howley P. M., Munger K., Harlow E. The human papilloma‐virus‐16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934–940
   PubMed Web of Science ®Google Scholar
• Whyte P., Buchkovich K. J., Horowitz J. M., Friend S. H., Raybuck M., Weinberg R. A., Harlow E. Association between an oncogene and an anti‐oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature 1988; 334: 124–128
   PubMed Web of Science ®Google Scholar
• Kaelin W. G., Ewen M. E., Livingston D. M. Definition of the minimal simian virus 40 large T antigen‐ and adenovirus EIA‐ binding domain in the retinoblastoma gene product. Mol. Cell. Biol. 1990; 10: 3761–3769
   PubMed Web of Science ®Google Scholar
• Hu Q., Dyson N., Harlow E. The regions of the retinoblastoma protein needed for binding to adenovirus El A or SV40 large T antigen are common sites for mutations. EMBO J. 1990; 9: 1147–1157
   PubMed Web of Science ®Google Scholar
• Ludlow J. W., DeCaprio J. A., Huang C. M., Lee W. H., Paucha E., Livingston D. M. SV40 large T antigen binds preferentially to an underphosphorylated member of the retinoblastoma susceptibility gene product family. Cell 1989; 56: 57–65
   PubMed Web of Science ®Google Scholar
• Defeo‐Jones D., Huang P. S., Jones R. E., Haskell K. M., Vuocolo G. A., Hanobik M. G., Huber H. E., Oliff A. Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product. Nature 1991; 352: 251–254
   PubMed Web of Science ®Google Scholar
• Huang S., Lee W. H., Lee E. Y. H. P. A cellular protein that competes with SV40 T antigen for binding to the retinoblastoma gene product. Nature 1991; 350: 160–162
   PubMed Web of Science ®Google Scholar
• Chellappan S. P., Hiebert S., Mudryj M., Horowitz J. M., Nevins J. R. The E2F transcription factor is a cellular target for the RB protein. Cell 1991; 65: 1053–1061
   PubMed Web of Science ®Google Scholar
• Robbins P. D., Horowitz J. M., Mulligan R. C. Negative regulation of human c‐fos expression by the retinoblastoma gene product. Nature 1990; 346: 668–671
   PubMed Web of Science ®Google Scholar
• Pietenpol J. A., Münger K., Howley P. M., Stein R. W., Moses H. L. Factor‐binding element in the human c‐myc promoter involved in transcriptional regulation by transforming growth factor β1 and by the retinoblastoma gene product. Proc. Natl. Acad. Sci. 1991; 88: 10227–10231
   PubMed Web of Science ®Google Scholar
• Kim S. J., Lee H. D., Robbins P. D., Busam K., Sporn M. B. Regulation of transforming growth factor PI gene expression by the product of the retinoblastoma susceptibility gene. Proc. Natl. Acad. Sci. 1991; 88: 3052–3056
   PubMed Web of Science ®Google Scholar
• Rustgi A. K., Dyson N., Bernards R. Amino‐terminal domains of c‐myc and N‐myc proteins mediate binding to the retinoblastoma gene product. Nature 1991; 352: 541–543
   PubMed Web of Science ®Google Scholar
• Horowitz J. M., Park S. H., Bogenmann E., Cheng J. C., Yandell D. W., Kaye F. J., Minna J. D., Dryja T. P., Weinberg R. A. Frequent inactivation of the retinoblastoma anti‐oncogene is restricted to a subset of human tumor cells. Proc. Natl. Acad. Sci. 1990; 87: 2175–2179
   Web of Science ®Google Scholar
• Weide R., Tiemann M., Pflüger K. H., Koppler H., Parviz B., Wacker H. H., Kreipe H. H., Havemann K., Parwaresch M. R. Altered expression of the human retinoblastoma gene product in human high grade non‐hodgkin's lymphomas. Proc. in Fifth international conference on malignant lymphoma. Lugano 1992; 45
   Google Scholar
• Stilgenbauer S., Döhner H., Bulgay‐Mörschel M., Weitz S., Bentz M., Lichter P. High frequency of monoallelic retinoblastoma gene deletion in B‐cell chronic lymphoid leukemia shown by interphase cytogenetics. Blood 1993; 81: 2118–2124
   PubMed Web of Science ®Google Scholar
• Towatari M., Adachi K., Kato H., Saito H. Absence of the human retinoblastoma gene product in the megakaryoblastic crisis of chronic myelogenouq leukemia. Blood 1991; 78: 2178–2181
   PubMed Web of Science ®Google Scholar
• Ahuja H. G., Jat P. S., Foti A., Bar‐Eli M., Cline M. J. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood 1991; 78: 3259–3268
   PubMed Web of Science ®Google Scholar
• Tang J. L., Yeh S. H., Chen P. J., Lin M. T., Tien H. F., Chang Y. Inactivation of the retinoblastoma gene in acute myelogenous leukemia. Br. J. Haematol. 1992; 82: 502–507
   PubMed Web of Science ®Google Scholar
• Weide R., Parviz B., Pfliiger K. H., Havemann K. Altered expression of the human retinoblastoma gene in monocytic leukemia. Br. J. Haematol. 1993; 83: 428–432
   PubMed Web of Science ®Google Scholar
• Zhu Y. M., Bradbury D., Russell N. Decreased retinoblastoma protein expression in acute myeloblastic leukemia is associated with the autonomous proliferation of clonogenic blasts. Br. J. Haematol. 1994; 86: 533–539
   PubMed Web of Science ®Google Scholar
• Dewald G. W., Kyle R. A., Hicks G. A., Greipp P. R. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood 1985; 66: 380–390
   PubMed Web of Science ®Google Scholar
• Gould J., Alexanian R., Goodacre A., Pathak S., Hecht B., Barlogie B. Plasma cell karyotype in multiple myeloma. Blood 1988; 71: 453–456
   PubMed Web of Science ®Google Scholar
• Dao D. D., Sawyer J. R., Epstein J., Hoover R. G., Barlogie B., Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia 1994; 8: 1280–1284
   PubMed Web of Science ®Google Scholar
• Corradini P., Inghirami G., Astolfi M., Ladetto M., Voena C., Ballerini P., Gu W., Nilsson K., Knowles D. M., Boccadoro M., Pileri A., Dalla‐Favera R. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 1994; 8: 758–767
   PubMed Web of Science ®Google Scholar
• Zandecki M., Facon T., Preudhomme C., Vanrumbeke M., Vachee A., Quesnel B., Lai J. L., Cosson A., Fenaux P. The retinoblastoma gene (RB‐1) status in multiple myeloma: a report on 35 cases. Leuk. Lymphoma 1995; 18: 497–503
   PubMed Web of Science ®Google Scholar
• Xu H. J., Hu S. X., Benedict W. F. Lack of nuclear RB protein staining in G0/middle GI cells: correlation to changes in total RB protein level. Oncogene 1991; 6: 1139–1146
   PubMed Web of Science ®Google Scholar
• Zhang X. G., Gaillard J. P., Robillard N., Lu Z. Y., Gu Z. J., Jourdan M., Boiron J. M., Bataille R., Klein B. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994; 83: 3654–3663
   PubMed Web of Science ®Google Scholar
• Juge‐Morineau N., Mellerin M. P., Francois S., Rapp M. J., Harousseau J. L., Amiot M., Bataille R. High incidence of deletions but infrequent inactivation of the retinoblastoma gene in human myeloma cells. Br. J. Haematol. 1995; 91: 664–667
   PubMed Web of Science ®Google Scholar
• Hawthorn L. A., Chapman R., Oscier D., Cowell J. K. The consistent 13q14 translocation breakpoint seen in chronic B‐cell leukemia (BCLL) involves deletion of the DI3S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene 1993; 8: 1415–1419
   PubMed Web of Science ®Google Scholar
• Keller E. T., Ershler W. B. Effect of IL‐6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J. Immunol. 1995; 154: 4091–4098
   PubMed Web of Science ®Google Scholar